ecrin-mdr-crcClinical2018Colorectal TumorsColorectal CarcinomaColorectal NeoplasmColorectal CancerColorectal NeoplasmsMetastatic colorectal cancerColorectal TumorsColorectal CarcinomaMetastatic Colorectal CancerColorectal NeoplasmColorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2261590CanadaArgentinaBelgiumUnited StatesCzechiaUnited KingdomItalyAustraliaChileGermanySpain2RegorafenibIpilimumabNivolumabNIVOLUMAB - 10mL vial - CommercialNIVOLUMAB - 4mL vial - CommercialTrametinibECRIN MDRActive, not recruitingfalseAn Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has SpreadThe purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.2018-02-152261590NCT033773612017-001830-24